AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Hospital business revenues increase 13.9% to Rs. 1,655 crore
This product will be manufactured at Lupin’s Nagpur facility in India
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Subscribe To Our Newsletter & Stay Updated